Acute toxicity evaluation of a novel ceramide analog for the treatment of breast cancer. 2021

Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
Department of Chemistry, Xavier University of Louisiana, 1 Drexel Dr., New Orleans, LA 70125, USA.

We have previously reported that treating triple-negative tumor bearing nude mice with intraperitoneal (ip) 10 mg/kg body weight of (S,E)-3-hydroxy-2-(2-hydroxybenzylidene)amino-N-tetradecylpropanamide, a ceramide analog, 5 days per week for 3 weeks, was shown not only to suppress tumor growth but also to reduce metastasis. Studies reported here focus on determining the toxicity of this drug in the nude mice. During the first study, treated animals (single intraperitoneal (ip) injection, 0, 40, 80 and 120 mg/kg body weight) were closely monitored for 14 days for any signs of illness or death. No mice were lost in any animal groups; however, hepatic serum enzymes were elevated, and hepatic and heart tissue damages were found in the highest dosage group. The subsequent study was performed using a lower dosage range (single ip injection, 0, 25, 50 and 75 mg/kg body weight), which resulted in no significant toxicity. All tested parameters were within normal ranges, with no observed irregularities. Our findings show that a single ip dose of this ceramide analog induced liver and heart toxicity at 120 mg/kg but not at doses of 80 mg/kg body weight or lower.

UI MeSH Term Description Entries

Related Publications

Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
January 2024, Anti-cancer drugs,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
April 2008, Expert opinion on investigational drugs,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
October 2018, Anti-cancer drugs,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
December 1993, Critical reviews in oncology/hematology,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
January 2020, Translational cancer research,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
January 1993, Acta poloniae pharmaceutica,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
May 2004, The Journal of pharmacology and experimental therapeutics,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
August 2021, Current oncology reports,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
December 1987, Cancer treatment reviews,
Tulasi Ponnapakkam, and Kyla Bongay-Williams, and Teresa Beamon, and Royce Hooks, and Degrick Cheatham, and Navneet Goyal, and Muralidharan Anbalagan, and Maryam Foroozesh
January 1984, Cancer,
Copied contents to your clipboard!